The Latest
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures
Skip to primary navigation
Skip to main content
Skip to footer
COUR Pharmaceuticals
Our Company
Leadership
Advisors
Partners
Contact
Our Technology
Pipeline
Autoimmune Diseases
Allergies
Rare Diseases
Gene Therapy
Our Clinical Trials
Publications & Media
Press Releases
Publications
Careers
Active Clinical Trials
CNP-104 Clinical Trial
Primary Biliary Cholangitis
Learn More